Get the Stockscreener App
15.18
3.19%
-0.50
After Hours:
15.22
0.04
+0.26%
Adma Biologics Inc stock is traded at $15.18, with a volume of 7.48M.
It is down -3.19% in the last 24 hours and down -10.50% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$15.68
Open:
$16.25
24h Volume:
7.48M
Relative Volume:
2.97
Market Cap:
$3.61B
Revenue:
$488.56M
Net Income/Loss:
$209.45M
P/E Ratio:
17.83
EPS:
0.8515
Net Cash Flow:
$40.61M
1W Performance:
-6.99%
1M Performance:
-10.50%
6M Performance:
-11.23%
1Y Performance:
-3.80%
1-Day Range:
$14.71
$16.60
1-Week Range:
$14.71
$16.60
52-Week Range:
$13.76
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
15.18 | 3.73B | 488.56M | 209.45M | 40.61M | 0.8515 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance - Finviz
Westfield Capital Management Co. LP Takes $74.87 Million Position in ADMA Biologics Inc $ADMA - MarketBeat
New ADMA Biologics CFO Takes Helm As Valuation Gap Draws Focus - Yahoo Finance
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics Inc (ADMA) Q4 2025 Earnings Call Highlights: Stro - GuruFocus
ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com
ADMA Biologics (ADMA) Reports Strong 2025 Results and Positive O - GuruFocus
ADMA Biologics Reports Strong Q4 2025 Earnings and Positive Outlook - Intellectia AI
ADMA Biologics Q4 2025 Earnings Call Transcript - MarketBeat
ADMA forecasts $635M revenue for 2026 as ASCENIV drives margin expansion and new supply deals extend growth runway - MSN
ADMA Biologics Q4 Earnings Call Highlights - Yahoo Finance
ADMA Biologics Says Brad Tade Is Retiring As Chief Financial Officer - TradingView
Earnings call transcript: ADMA Biologics reports strong Q4 2025 growth - Investing.com
ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results - MarketBeat
ADMA BIOLOGICS, INC. SEC 10-K Report - TradingView
(ADMA) ADMA Biologics Expects 2026 Revenue to Exceed $635M, vs. FactSet Est of $633.8M - marketscreener.com
Adma Biologics: Fourth Quarter Financial Overview - Bitget
ADMA Biologics Announces CFO Transition and Leadership Change - TipRanks
Adma Biologics: Q4 Earnings Snapshot - Barchart.com
ADMA Biologics CFO Brad Tade retires; Terry Kohler promoted to CFO - TradingView
ADMA Biologics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
ADMA Biologics earnings up next: Can momentum match lofty targets? By Investing.com - Investing.com Canada
ADMA Biologics earnings up next: Can momentum match lofty targets? - Investing.com India
Aug Outlook: Is ADMA Biologics Inc attractive for institutional investorsGap Down & Weekly High Return Stock Opportunities - baoquankhu1.vn
Aug Outlook: Whats the beta of ADMA Biologics Inc stockMarket Activity Recap & Short-Term Swing Trade Alerts - baoquankhu1.vn
ADMA Biologics to Announce Q4 Earnings on February 25 - Intellectia AI
Preview: ADMA Biologics's Earnings - Benzinga
What To Expect From ADMA Biologics Inc (ADMA) Q4 2025 Earnings - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With A 59.42% Potential Upside - DirectorsTalk Interviews
ADMA Biologics (ADMA) to Release Quarterly Earnings on Monday - MarketBeat
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Aberdeen Group plc Increases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics CEO Sale And Options Activity Versus Valuation And Momentum - Yahoo Finance
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
Adam Grossman, president of Adma Biologics, sells $337,679 in shares By Investing.com - Investing.com South Africa
Adam Grossman, president of Adma Biologics, sells $337,679 in shares - Investing.com
(ADMA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ADMA Biologics Inc (ADMA) Stock Analysis: Unlocking a 59.52% Upside in the Biotech Arena - DirectorsTalk Interviews
Public Sector Pension Investment Board Acquires 116,867 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Assessing ADMA Biologics (ADMA) Valuation After Recent Share Price Rebound - Sahm
Market Leaders: Can ADMA Biologics Inc outperform in the next rallyJuly 2025 Analyst Calls & Risk Controlled Stock Alerts - baoquankhu1.vn
What are ADMA Biologics Inc.’s growth leversJuly 2025 Review & Community Trade Idea Sharing Platform - mfd.ru
Aug Movers: What is the cash position of REPXJuly 2025 Weekly Recap & Target Return Focused Picks - baoquankhu1.vn
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note - Nasdaq
Navellier & Associates Inc. Has $176,000 Stake in ADMA Biologics Inc $ADMA - MarketBeat
New York State Common Retirement Fund Decreases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Principal Financial Group Inc. Cuts Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc (ADMA) Stock Analysis: Attractive 56.22% Upside Potential For Investors - DirectorsTalk Interviews
Renaissance Group LLC Has $7.57 Million Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
(ADMA) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing ADMA Biologics (ADMA) Valuation After Growing Analyst Optimism On Earnings And Plasma Therapy Pipeline - Yahoo Finance
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Feb 17 '26 |
Sale |
16.08 |
21,000 |
337,680 |
2,284,379 |
0.11%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):